Inovio Pharmaceuticals (INO)
(Delayed Data from NSDQ)
$11.00 USD
+0.04 (0.36%)
Updated May 24, 2024 03:59 PM ET
After-Market: $10.99 -0.01 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Inovio Pharmaceuticals, Inc. [INO]
Reports for Purchase
Showing records 301 - 320 ( 363 total )
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
On the Road to Curing Cancer: Recent Developments and Future Outlook
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: RAMAKANTH S
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Ebola Trial Initiated; 2015 1Q Financial Results; Reiterate Buy
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: CHEN Y
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Hepatitis B Trial Initiation; Strong T Cell Responses in Head and Neck Cancer; Reiterate Buy
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: CHEN Y
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Inovio Leads $45 Million Ebola Program; Reiterate Buy
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: CHEN Y
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Full-Year 2014 Financial Results; Reiterate Buy
Provider: H.C. WAINWRIGHT & CO., INC.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
King of Synthetic Vaccines; Initiate with Buy and $17 Price Target
Provider: H.C. WAINWRIGHT & CO., INC.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Interim Analysis of the Phase I Reported Unprecedented Immune Responses.
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Interim Analysis of the Phase I Reported Unprecedented Immune Responses.
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Initiates a Phase I Trial of Universal Flu Vaccine in Elderly
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Inovio Initiates a Phase I Trial of Universal Flu Vaccine in Elderly
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are placing Inovio Pharmaceuticals under review due to the departure of the covering analyst
Provider: RODMAN & RENSHAW, CO.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
SYNCON BASED AVIAN FLU VACCINE - MULTIPLE TRIALS GENERATING TITERS
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
SYNCON BASED AVIAN FLU VACCINE - MULTIPLE TRIALS GENERATING TITERS
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R